Over 55 million folks worldwide have dementia. This mind-robbing illness has a big impact on society and the financial system, so scientists are working exhausting to search out methods to deal with or stop it. One of many avenues being explored is the brand new weight-loss jab, Wegovy.
Though age is by far the best threat issue for dementia, weight problems and sort 2 diabetes are additionally main threat components for growing the situation. That is the place Wegovy and its sister drug, Ozempic, come into the image. Wegovy and Ozempic, a drug to deal with sort 2 diabetes, each comprise the identical lively substance referred to as semaglutide.
Semaglutide mimics the motion of a hormone, GLP-1, that’s usually launched from the intestine after a meal. The hormone latches on to receptors within the pancreas that stimulate the discharge of insulin, which helps decrease blood sugar ranges.
ALSO READ: Smoking: 4 compelling causes to stop for good
Nonetheless, these receptors are additionally in “reward centres” of the mind, together with in areas controlling consuming. Provided that semaglutide is ready to cross the blood-brain barrier (the protecting layer across the mind), it’s more likely to straight modify mind exercise to make folks really feel much less hungry.
A Danish examine that adopted folks with sort 2 diabetes for 5 years discovered these on semaglutide or liraglutide (one other diabetes drug) had a decrease incidence of dementia. Kind 2 diabetes is extra strongly related to vascular dementia and never Alzheimer’s illness (the most typical type of dementia), so solely sure types of dementia could be diminished by semaglutide.
Nonetheless, two medical trials which started in 2021 are testing whether or not each day oral doses of semaglutide will sluggish illness progress in folks within the early phases of Alzheimer’s. Because it takes a very long time to develop the illness, trials are anticipated to be accomplished in 2026.
Alzheimer’s illness is believed to originate in particular areas of the cerebral cortex – the area answerable for reminiscences and spatial navigation. However receptors for GLP-1 have been not detected within the cortex, making it unlikely that semaglutide straight prompts reminiscence networks. So how would possibly the drug deal with the illness?
The brains of Alzheimer’s illness sufferers accumulate sticky plaques of amyloid-beta in addition to clumps of tau proteins inside mind cells. These are thought to disrupt cognition.
A medical trial is underway right here on the College of Oxford that can particularly look at tau ranges in individuals who have excessive ranges of amyloid-beta however haven’t (but) developed dementia. It’s hoped that semaglutide will scale back cortical tau ranges, resulting in diminished charges of cognitive decline.
ALSO READ: Breaking the silence: The advantages of revealing psychological well being at work
Medicine just lately permitted within the US to deal with Alzheimer’s goal amyloid-beta plaques. However these medication have proved controversial, with sufferers requiring hour-long infusions each two to 4 weeks.
A lot of these drug in all probability additionally goal amyloid-beta round blood vessels, resulting in doubtlessly life-threatening side-effects equivalent to bleeds within the mind. Different methods are subsequently fascinating, and that is the place semaglutide might shine.
ALSO READ: TNT Africa’s ‘Paper Spiders’ spotlights psychological well being consciousness
Irritation
The important thing hyperlink between semaglutide and decreasing Alzheimer’s illness could be neuroinflammation – a state wherein the mind is chronically infected.
Neuroinflammation damages the blood-brain barrier, which is disrupted in each Alzheimer’s illness and vascular dementia. The Oxford trial inspecting tau can also be how semaglutide impacts neuroinflammation (there are solutions that semaglutide is anti-inflammatory in folks with weight problems).
It additionally reduces neuroinflammation within the brains of mice, and restores glucose transport throughout the blood-brain barrier (one thing that’s disrupted in folks with Alzheimer’s).
ALSO READ: How music can be utilized as remedy for psychological well being
One other drug, memantine – initially developed to deal with diabetes – was repurposed to ease signs of Alzheimer’s illness, and continues to be prescribed for that use at present. Now we eagerly await the outcomes of the next-generation of diabetes and weight-loss medication to see if they will stop or deal with Alzheimer’s illness.
Within the meantime, there are life-style modifications you may make to cut back your threat of growing the illness. These embody protecting lively, consuming a nutritious diet, sustaining a wholesome weight, and quitting smoking.
Article by:
Tim Viney. Profession Improvement Fellow, College of Oxford
Barbara Sarkany. DPhil Candidate, Alzheimer’s, College of Oxford
This text is republished from The Dialog below a Inventive Commons license. Learn the unique article.
CLICK HERE TO READ MORE ARTICLES BY THE CONVERSATION
